{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:14:00Z","timestamp":1789607640305,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["UKDRI-3003"],"award-info":[{"award-number":["UKDRI-3003"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/T04604X\/1"],"award-info":[{"award-number":["MR\/T04604X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Alzheimer\u2019s disease, among other neurodegenerative disorders, spans decades in individuals\u2019 life and exhibits complex progression, symptoms and pathophysiology. Early diagnosis is essential for disease prevention and therapeutic intervention. Genetics may help identify individuals at high risk. As thousands of genetic variants may contribute to the genetic risk of Alzheimer\u2019s disease, the polygenic risk score (PRS) approach has been shown to be useful for disease risk prediction. The\n                      <jats:italic>APOE<\/jats:italic>\n                      -\n                      <jats:italic>\u03b5<\/jats:italic>\n                      4 allele is a known common variant associated with high risk to AD, but also associated with earlier onset. Rare variants usually have higher effect sizes than common ones; their impact may not be well captured by the PRS. Instead of standardised PRS, we propose to calculate the disease probability as a measure of disease risk that allows comparison between individuals.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We estimate AD risk as a probability based on PRS and separately accounting for APOE, AD rare variants and the disease prevalence in age groups. The mathematical framework makes use of genetic variants effect sizes from summary statistics and AD disease prevalence in age groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The AD probability varies with respect to age,\n                      <jats:italic>APOE<\/jats:italic>\n                      status and presence of rare variants. In age group 65+, the probability of AD grows from 0.03 to 0.18 (without APOE) and 0.07 to 0.7 (APOE e4e4 carriers) as PRS increases. In 85+, these values are 0.08\u20130.6 and 0.3\u20130.85. Presence of rare mutations, e.g. in\n                      <jats:italic>TREM2<\/jats:italic>\n                      , may increase the probability (in 65+) from 0.02 at the negative tail of the PRS to 0.3.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our approach accounts for the varying disease prevalence in different genotype and age groups when modelling the\n                      <jats:italic>APOE<\/jats:italic>\n                      and rare genetic variants risk in addition to PRS. This approach has potential for use in a clinical setting and can easily be updated for novel rare variants and for other populations or confounding factors when appropriate genome-wide association data become available.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-021-00884-7","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T06:03:50Z","timestamp":1629180230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Probability of Alzheimer\u2019s disease based on common and rare genetic variants"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1784-5483","authenticated-orcid":false,"given":"Valentina","family":"Escott-Price","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Michael","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"issue":"3","key":"884_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41588-018-0311-9","volume":"51","author":"IE Jansen","year":"2019","unstructured":"Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. Nat Genet. 2019;51(3):404\u201313. https:\/\/doi.org\/10.1038\/s41588-018-0311-9.","journal-title":"Nat Genet"},{"issue":"3","key":"884_CR2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414\u201330. https:\/\/doi.org\/10.1038\/s41588-019-0358-2.","journal-title":"Nat Genet"},{"issue":"12","key":"884_CR3","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/ng.2802","volume":"45","author":"JC Lambert","year":"2013","unstructured":"Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45(12):1452\u20138. https:\/\/doi.org\/10.1038\/ng.2802.","journal-title":"Nat Genet"},{"issue":"1","key":"884_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41398-018-0150-6","volume":"8","author":"RE Marioni","year":"2018","unstructured":"Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, Hill WD, et al. GWAS on family history of Alzheimer\u2019s disease. Transl Psychiatry. 2018;8(1):99. https:\/\/doi.org\/10.1038\/s41398-018-0150-6.","journal-title":"Transl Psychiatry"},{"key":"884_CR5","doi-asserted-by":"crossref","unstructured":"Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 Variants in Alzheimer\u2019s Disease. N Engl J Med. 2013;368(2):117\u201327.","DOI":"10.1056\/NEJMoa1211851"},{"issue":"2","key":"884_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer\u2019s disease. N Engl J Med. 2013;368(2):107\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1211103.","journal-title":"N Engl J Med"},{"issue":"9","key":"884_CR7","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/ng.3916","volume":"49","author":"R Sims","year":"2017","unstructured":"Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer\u2019s disease. Nat Genet. 2017;49(9):1373\u201384. https:\/\/doi.org\/10.1038\/ng.3916.","journal-title":"Nat Genet"},{"issue":"4","key":"884_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.cell.2005.02.008","volume":"120","author":"RE Tanzi","year":"2005","unstructured":"Tanzi RE, Bertram L. Twenty years of the Alzheimer\u2019s disease amyloid hypothesis: a genetic perspective. Cell. 2005;120(4):545\u201355. https:\/\/doi.org\/10.1016\/j.cell.2005.02.008.","journal-title":"Cell."},{"issue":"1","key":"884_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13073-017-0489-y","volume":"9","author":"CM Lewis","year":"2017","unstructured":"Lewis CM, Vassos E. Prospects for using risk scores in polygenic medicine. Genome Med. 2017;9(1):96. https:\/\/doi.org\/10.1186\/s13073-017-0489-y.","journal-title":"Genome Med"},{"issue":"7","key":"884_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamapsychiatry.2015.0346","volume":"72","author":"E Agerbo","year":"2015","unstructured":"Agerbo E, Sullivan PF, Vilhjalmsson BJ, Pedersen CB, Mors O, Borglum AD, et al. Polygenic Risk Score, Parental Socioeconomic Status, Family History of Psychiatric Disorders, and the Risk for Schizophrenia: A Danish Population-Based Study and Meta-analysis. JAMA Psychiatry. 2015;72(7):635\u201341. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.0346.","journal-title":"JAMA Psychiatry"},{"key":"884_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.neurobiolaging.2016.07.018","volume":"49","author":"V Escott-Price","year":"2017","unstructured":"Escott-Price V, Shoai M, Pither R, Williams J, Hardy J. Polygenic score prediction captures nearly all common genetic risk for Alzheimer\u2019s disease. Neurobiol Aging. 2017;49:214 e7- e11.","journal-title":"Neurobiol Aging"},{"issue":"3","key":"884_CR12","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/gim.2016.103","volume":"19","author":"K Lall","year":"2017","unstructured":"Lall K, Magi R, Morris A, Metspalu A, Fischer K. Personalized risk prediction for type 2 diabetes: the potential of genetic risk scores. Genet Med. 2017;19(3):322\u20139. https:\/\/doi.org\/10.1038\/gim.2016.103.","journal-title":"Genet Med"},{"issue":"22","key":"884_CR13","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1161\/CIRCULATIONAHA.116.024436","volume":"135","author":"P Natarajan","year":"2017","unstructured":"Natarajan P, Young R, Stitziel NO, Padmanabhan S, Baber U, Mehran R, et al. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. Circulation. 2017;135(22):2091\u2013101. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024436.","journal-title":"Circulation."},{"issue":"2","key":"884_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/ana.24999","volume":"82","author":"V Escott-Price","year":"2017","unstructured":"Escott-Price V, Myers AJ, Huentelman M, Hardy J. Polygenic risk score analysis of pathologically confirmed Alzheimer disease. Ann Neurol. 2017;82(2):311\u20134. https:\/\/doi.org\/10.1002\/ana.24999.","journal-title":"Ann Neurol"},{"issue":"4","key":"884_CR15","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S1474-4422(19)30435-1","volume":"19","author":"SJ Andrews","year":"2020","unstructured":"Andrews SJ, Fulton-Howard B, Goate A. Interpretation of risk loci from genome-wide association studies of Alzheimer\u2019s disease. Lancet Neurol. 2020;19(4):326\u201335. https:\/\/doi.org\/10.1016\/S1474-4422(19)30435-1.","journal-title":"Lancet Neurol"},{"issue":"11","key":"884_CR16","doi-asserted-by":"publisher","first-page":"reviews3014","DOI":"10.1186\/gb-2002-3-11-reviews3014","volume":"3","author":"A Tandon","year":"2002","unstructured":"Tandon A, Fraser P. The presenilins. Genome Biol. 2002;3(11):reviews3014.","journal-title":"Genome Biol"},{"issue":"6","key":"884_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nrg2361","volume":"9","author":"M Slatkin","year":"2008","unstructured":"Slatkin M. Linkage disequilibrium--understanding the evolutionary past and mapping the medical future. Nat Rev Genet. 2008;9(6):477\u201385. https:\/\/doi.org\/10.1038\/nrg2361.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"884_CR18","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1038\/s41467-019-11558-2","volume":"10","author":"J Deelen","year":"2019","unstructured":"Deelen J, Evans DS, Arking DE, Tesi N, Nygaard M, Liu X, et al. A meta-analysis of genome-wide association studies identifies multiple longevity genes. Nat Commun. 2019;10(1):3669. https:\/\/doi.org\/10.1038\/s41467-019-11558-2.","journal-title":"Nat Commun"},{"issue":"2","key":"884_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106\u201318. https:\/\/doi.org\/10.1038\/nrneurol.2012.263.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"884_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12933-016-0329-1","volume":"15","author":"D El-Lebedy","year":"2016","unstructured":"El-Lebedy D, Raslan HM, Mohammed AM. Apolipoprotein E gene polymorphism and risk of type 2 diabetes and cardiovascular disease. Cardiovasc Diabetol. 2016;15(1):12. https:\/\/doi.org\/10.1186\/s12933-016-0329-1.","journal-title":"Cardiovasc Diabetol"},{"key":"884_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2147\/CLEP.S213228","volume":"11","author":"J Garre-Olmo","year":"2019","unstructured":"Garre-Olmo J, Ponjoan A, Inoriza JM, Blanch J, Sanchez-Perez I, Cubi R, et al. Survival, effect measures, and impact numbers after dementia diagnosis: a matched cohort study. Clin Epidemiol. 2019;11:525\u201342. https:\/\/doi.org\/10.2147\/CLEP.S213228.","journal-title":"Clin Epidemiol"},{"issue":"2","key":"884_CR22","doi-asserted-by":"publisher","first-page":"408","DOI":"10.2105\/AJPH.2014.301935","volume":"105","author":"SE Tom","year":"2015","unstructured":"Tom SE, Hubbard RA, Crane PK, Haneuse SJ, Bowen J, McCormick WC, et al. Characterization of dementia and Alzheimer\u2019s disease in an older population: updated incidence and life expectancy with and without dementia. Am J Public Health. 2015;105(2):408\u201313. https:\/\/doi.org\/10.2105\/AJPH.2014.301935.","journal-title":"Am J Public Health"},{"key":"884_CR23","doi-asserted-by":"crossref","unstructured":"Leonenko G, Baker E, Stevenson-Hoare J, Sierksma A, Fiers M, Williams J, et al. Identifying individuals with high risk of Alzheimer\u2019s disease using polygenic risk scores. Nat Commun. 2021;12:4506.","DOI":"10.1038\/s41467-021-24082-z"},{"issue":"3","key":"884_CR24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000289597","volume":"69","author":"J Wang","year":"2010","unstructured":"Wang J, Shete S. Using both cases and controls for testing hardy-weinberg proportions in a genetic association study. Hum Hered. 2010;69(3):212\u20138. https:\/\/doi.org\/10.1159\/000289597.","journal-title":"Hum Hered"},{"key":"884_CR25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.neurobiolaging.2017.07.001","volume":"59","author":"C Bellenguez","year":"2017","unstructured":"Bellenguez C, Charbonnier C, Grenier-Boley B, Quenez O, Le Guennec K, Nicolas G, et al. Contribution to Alzheimer\u2019s disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiol Aging. 2017;59:220 e1- e9.","journal-title":"Neurobiol Aging"},{"issue":"19","key":"884_CR26","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","volume":"80","author":"LE Hebert","year":"2013","unstructured":"Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80(19):1778\u201383. https:\/\/doi.org\/10.1212\/WNL.0b013e31828726f5.","journal-title":"Neurology."},{"issue":"5","key":"884_CR27","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/gim.2015.117","volume":"18","author":"C Van Cauwenberghe","year":"2016","unstructured":"Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016;18(5):421\u201330. https:\/\/doi.org\/10.1038\/gim.2015.117.","journal-title":"Genet Med"},{"issue":"2","key":"884_CR28","doi-asserted-by":"publisher","first-page":"e576","DOI":"10.1212\/NXG.0000000000000576","volume":"7","author":"KM Bakulski","year":"2021","unstructured":"Bakulski KM, Vadari HS, Faul JD, Heeringa SG, Kardia SLR, Langa KM, et al. Cumulative Genetic Risk and APOE epsilon4 Are Independently Associated With Dementia Status in a Multiethnic, Population-Based Cohort. Neurol Genet. 2021;7(2):e576. https:\/\/doi.org\/10.1212\/NXG.0000000000000576.","journal-title":"Neurol Genet"},{"issue":"7","key":"884_CR29","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1093\/brain\/awaa164","volume":"143","author":"CC Fan","year":"2020","unstructured":"Fan CC, Banks SJ, Thompson WK, Chen CH, McEvoy LK, Tan CH, et al. Sex-dependent autosomal effects on clinical progression of Alzheimer's disease. Brain. 2020;143(7):2272\u201380. https:\/\/doi.org\/10.1093\/brain\/awaa164.","journal-title":"Brain."},{"issue":"3","key":"884_CR30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41588-018-0059-2","volume":"50","author":"AF Pardinas","year":"2018","unstructured":"Pardinas AF, Holmans P, Pocklington AJ, Escott-Price V, Ripke S, Carrera N, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 2018;50(3):381\u20139. https:\/\/doi.org\/10.1038\/s41588-018-0059-2.","journal-title":"Nat Genet"},{"key":"884_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cobeha.2014.07.001","volume":"2","author":"E Rees","year":"2015","unstructured":"Rees E, O'Donovan MC, Owen MJ. Genetics of schizophrenia. Curr Opin Behav Sci. 2015;2:8\u201314. https:\/\/doi.org\/10.1016\/j.cobeha.2014.07.001.","journal-title":"Curr Opin Behav Sci"},{"issue":"3","key":"884_CR32","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779. https:\/\/doi.org\/10.1371\/journal.pmed.1001779.","journal-title":"PLoS Med"}],"updated-by":[{"DOI":"10.1186\/s13195-021-00898-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000}}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00884-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-021-00884-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00884-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T11:16:16Z","timestamp":1632136576000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00884-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["884"],"URL":"https:\/\/doi.org\/10.1186\/s13195-021-00884-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-448021\/v1","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]},"assertion":[{"value":"23 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13195-021-00898-1","URL":"https:\/\/doi.org\/10.1186\/s13195-021-00898-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}